Bortezomib Injection IP Winzomib 2

Name: Bortezomib Injection IP Winzomib 2
Brand: PHP Lifesciences LLP
Price: 660 INR
Availability: InStock

Price 660 INR/ Vial

Get a Price/Quote

MOQ : 10 Vials

Bortezomib Injection IP Winzomib 2 Specification

Salt Composition
Bortezomib 2 mg

Dosage Form
Injection (Lyophilized Powder for Reconstitution)

Indication
Multiple Myeloma and Mantle Cell Lymphoma

Feature
Cytotoxic Antineoplastic Agent

Application

Ph Level
Neutral (for reconstituted solution)

Physical Color/Texture
White to off-white lyophilized powder

Fermentation Smell
Odorless

Storage Instructions
Store below 25C. Protect from light. Do not freeze.

Shelf Life
2 Years

Reconstitution Instructions
Reconstitute with 2.0 mL sterile normal saline

Brand Name
Winzomib 2

Prescription/OTC
Prescription only

Stability after Reconstitution
Use within 8 hours at room temperature

USP/Pharmacopoeia Standard
IP (Indian Pharmacopoeia)

Container Material
Glass vial with rubber stopper and aluminium seal

Route of Administration
Intravenous (IV) or Subcutaneous (SC) after reconstitution

Intended Patient Population
Adults with diagnosed multiple myeloma or mantle cell lymphoma

Packaging Type
Single-use vial

Strength
2 mg per vial

Bortezomib Injection IP Winzomib 2 Trade Information

Minimum Order Quantity
10 Vials

Supply Ability
1000 Vials Per Month

Delivery Time
7 Days

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

About Bortezomib Injection IP Winzomib 2

Discover distinguished treatment with Bortezomib Injection IP Winzomib 2 - the top-drawer solution for adults battling multiple myeloma or mantle cell lymphoma. Now available at an exceptional Price Cut, this pivotal oncology medication comes in a single-use 2 mg vial, designed for intravenous or subcutaneous use after reconstitution with sterile saline. Utilise Offer for a limited time only! Its neutral pH, odorless nature, and cytotoxic effectiveness meet strict Indian Pharmacopoeia standards. Packaged in a secure glass vial and tailored for superior patient safety, Winzomib 2 ensures reliability when it matters most.

Comprehensive Usage & Competitive Advantages

Winzomib 2 is administered either intravenously or subcutaneously following meticulous reconstitution, making it adaptable to clinical requirements. Distinguished by its pivotal role in chemotherapy, it offers top-drawer efficacy against multiple myeloma and mantle cell lymphoma. The product's neutral pH, stability for eight hours post-reconstitution, and impeccable IP standards provide additional advantages, earning trust with healthcare professionals. Its clear handling instructions, robust packaging, and efficient pharmacological action make it the preferred choice for adults in need of advanced oncology care.

Sample Policy, Certification & Global Delivery

Winzomib 2 caters adeptly to the export market, presenting competitive supply policies and options for tailored Quotation. Backed by necessary certifications, this product aligns with regulatory and quality requirements worldwide. Delivery times are efficiently managed, ensuring prompt access for dealers, distributors, and wholesalers. Our dedicated supply chain supports seamless global distribution, making Winzomib 2 the reliable choice for partners needing fast, certified, and flexible oncology solutions in India and beyond.

FAQ's of Bortezomib Injection IP Winzomib 2:

Q: How should Winzomib 2 be reconstituted for administration?

A: Winzomib 2 should be reconstituted with 2.0 mL of sterile normal saline, resulting in a neutral pH solution. The reconstituted solution should be used within 8 hours at room temperature.

Q: What are the main indications for using Bortezomib Injection IP Winzomib 2?

A: Bortezomib Injection IP Winzomib 2 is indicated for the treatment of adults diagnosed with multiple myeloma or mantle cell lymphoma as part of chemotherapy protocols.

Q: When should the reconstituted solution of Winzomib 2 be administered?

A: The reconstituted solution should be administered within 8 hours of preparation to ensure utmost stability and effectiveness.

Q: Where can healthcare professionals obtain Quotation and supply details for Winzomib 2?

A: Dealers, distributors, exporters, suppliers, and traders can request Quotation and supply details directly from the manufacturer or authorized sellers, who cater to both domestic and export markets.

Q: What benefits does Winzomib 2 offer compared to other cytotoxic antineoplastic agents?

A: Winzomib 2 offers pivotal advantages including adherence to Indian Pharmacopoeia standards, stable reconstitution, superior packaging, and proven efficacy for multiple myeloma and mantle cell lymphoma, making it a top-drawer option in oncology.